Infliximab and adalimumab
( DrugBank: Infliximab / KEGG DRUG: Infliximab )
2 diseases
96. クローン病
臨床試験数 : 2,737 / 薬物数 : 1,197 - (DrugBank : 240) / 標的遺伝子数 : 182 - 標的パスウェイ数 : 221
Showing 1 to 10 of 24 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05928039 (ClinicalTrials.gov) | October 25, 202320231025 | 13/6/202320230613 | PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ile ... | PATHFINDER: A Pragmatic, Active-comparator, Parallel-group, Randomized Trial to Evaluate the Optimal First-line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease PATHFINDER: A Pragmatic, Active-comparator, Parallel-group, Randomized Trial to Evaluate the Optimal ... | Crohn Disease | Biological: TNFa Antagonist - Infliximab;Biological: TNFa Antagonist - Adalimumab;Biological: Anti-IL12/23 or anti-IL23 - Ustekinumab;Biological: Anti-IL12/23 or anti-IL23 - Risankizumab;Biological: Anti-integrin - Vedolizumab IV;Biological: Anti-integrin - Vedolizumab IV and SC Biological: TNFa Antagonist - Infliximab;Biological: TNFa Antagonist - Adalimumab;Biological: Anti-I ... | University of Calgary | Alimentiv Inc. | Recruiting | 18 Years | N/A | All | 297 | Phase 4 | Canada |
| 2 | EUCTR2020-001811-26-BE (EUCTR) | 18/11/202120211118 | 22/07/202120210722 | IBD under control with less medication | De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring - FREE-study De-escalation of anti-TNF therapy in adolescents andyoung adults with IBD with tight faecal calprote ... | Crohn's disease, ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Crohn's disease, ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] ... | Trade Name: Remicade INN or Proposed INN: INFLIXIMAB Trade Name: Flixabi INN or Proposed INN: INFLIXIMAB Trade Name: Inflectra INN or Proposed INN: INFLIXIMAB Trade Name: Remsima INN or Proposed INN: INFLIXIMAB Trade Name: Zessly INN or Proposed INN: INFLIXIMAB Trade Name: Humira INN or Proposed INN: ADALIMUMAB Trade Name: Amgevita INN or Proposed INN: ADALIMUMAB Trade Name: Hulio INN or Proposed INN: ADALIMUMAB Trade Name: Remicade INN or Proposed INN: INFLIXIMAB Trade Name: Flixabi INN or Proposed INN: INFLIXIMA ... | University Medical Center Groningen | NULL | Not Recruiting | Female: yes Male: yes | 148 | Phase 4 | Netherlands;Belgium;Spain | ||
| 3 | EUCTR2019-002942-19-NO (EUCTR) | 16/03/202120210316 | 12/10/202020201012 | Nordic study of treatment strategy in inflammatory bowel disease | NORDTREATThe Nordic IBD treatment strategy trial – a randomized controlled trial of access to a protein profile NORDTREATThe Nordic IBD treatment strategy trial – a randomized controlled trial of access to a prot ... | Crohn's disease and Ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Crohn's disease andUlcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C0 ... | Trade Name: Remicade Trade Name: Humira Trade Name: Imurel Trade Name: Puri-nethol | Region Örebro län | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 4 | Norway;Denmark;Iceland | ||
| 4 | EUCTR2019-002942-19-DK (EUCTR) | 12/03/202120210312 | 05/11/202020201105 | Nordic study of treatment strategy in inflammatory bowel disease | NORDTREATThe Nordic IBD treatment strategy trial – a randomized controlled trial of access to a protein profile NORDTREATThe Nordic IBD treatment strategy trial – a randomized controlled trial of access to a prot ... | Crohn's disease and Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0;Classification code 10013099;Term: Disease Crohns;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Crohn's disease andUlcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;T ... | Trade Name: Remicade INN or Proposed INN: INFLIXIMAB Trade Name: Humira INN or Proposed INN: ADALIMUMAB Trade Name: Imurel INN or Proposed INN: Azathioprine Trade Name: Puri-nethol INN or Proposed INN: MERCAPTOPURINE Trade Name: Remicade INN or Proposed INN: INFLIXIMAB Trade Name: Humira INN or Proposed INN: ADALIMUMAB ... | Region Örebro län | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 4 | Denmark;Iceland | ||
| 5 | NCT04646187 (ClinicalTrials.gov) | March 11, 202120210311 | 20/11/202020201120 | De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease | De-escalation of Anti-TNF Therapy in Adolescents and Young Adults With IBD With Tight Faecal Calprotectin and Trough Level Monitoring De-escalation of Anti-TNF Therapy in Adolescents andYoung Adults With IBD With Tight Faecal Calprote ... | Inflammatory Bowel Diseases;Crohn Disease;Colitis, Ulcerative | Biological: Infliximab;Biological: Adalimumab | University Medical Center Groningen | European Crohn´s and Colitis Organisation;Bühlmann Laboratories AG | Enrolling by invitation | 12 Years | 25 Years | All | 148 | Phase 4 | Belgium;Netherlands;Spain |
| 6 | EUCTR2019-002942-19-IS (EUCTR) | 25/01/202120210125 | 31/05/202420240531 | Nordic study of treatment strategy in inflammatory bowel disease | NORDTREATThe Nordic IBD treatment strategy trial – a randomized controlled trial of access to a protein profile NORDTREATThe Nordic IBD treatment strategy trial – a randomized controlled trial of access to a prot ... | Crohn's disease and Ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Crohn's disease andUlcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C0 ... | Trade Name: Remicade Trade Name: Humira Trade Name: Imurel Trade Name: Puri-nethol Trade Name: Metotrexat Trade Name: Folacin Trade Name: Remicade Trade Name: Humira Trade Name: Imurel Trade Name: Puri-nethol Trade Name: Metotrexa ... | Region Örebro län | NULL | Not Recruiting | Female: yes Male: yes | 250 | Phase 4 | Denmark;Iceland | ||
| 7 | EUCTR2020-001811-26-NL (EUCTR) | 30/09/202020200930 | 08/07/202020200708 | IBD under control with less medication | De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring - FREE-study De-escalation of anti-TNF therapy in adolescents andyoung adults with IBD with tight faecal calprote ... | Crohn's disease, ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Crohn's disease, ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] ... | Trade Name: Remicade INN or Proposed INN: INFLIXIMAB Trade Name: Flixabi INN or Proposed INN: INFLIXIMAB Trade Name: Inflectra INN or Proposed INN: INFLIXIMAB Trade Name: Remsima INN or Proposed INN: INFLIXIMAB Trade Name: Zessly INN or Proposed INN: INFLIXIMAB Trade Name: Humira INN or Proposed INN: ADALIMUMAB Trade Name: Amgevita INN or Proposed INN: ADALIMUMAB Trade Name: Hulio INN or Proposed INN: ADALIMUMAB Trade Name: Remicade INN or Proposed INN: INFLIXIMAB Trade Name: Flixabi INN or Proposed INN: INFLIXIMA ... | University Medical Center Groningen | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 4 | Netherlands;Belgium;Spain | ||
| 8 | NCT04131504 (ClinicalTrials.gov) | October 16, 201920191016 | 16/10/201920191016 | Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION) | A Multi-Center, Prospective Study to Discover a Companion Diagnostic for Biologics Targeting TNF | Crohn's Disease;IBD | Drug: Infliximab;Drug: Adalimumab | Children's Hospital Medical Center, Cincinnati | The Leona M. and Harry B. Helmsley Charitable Trust | Completed | 1 Year | 22 Years | All | 239 | United States | |
| 9 | JPRN-jRCT1031190056 (jRCT1031190056) | 30/09/201920190930 | 17/07/201920190717 | E6011-CS1 study | Research for medicinal predictive marker on Crohn's disease - E6011-CS1 study | Crohn's disease Crohn's disease;D003424;Crohn's disease | Study1:Evaluate the disease activity and collect the blood according to the schedule as below. Amount of blood collection should be about 15mL at screening test, after the beginning of the study, about 12.5mL per visit. 1.Adalimumab:At the beginning of the study, after that, 2, 4, 12, 24, 52 weeks after or at the termination 2.Infliximab:At the beginning of the study,after that, 2, 6, 14, 22, 54 weeks after or at the termination 3. Ustekinumab:At the beginning of the study,after that, 2, 8, 20, 32, 56weeks after or at the termination Study2:None. Study1:Evaluate the disease activity andcollect the blood according to the schedule as below. Amount ... | Mikami Yohei | EA Pharma Co.,Ltd. | Complete | >= 16age old | Not applicable | Both | 32 | N/A | NULL |
| 10 | NCT03885713 (ClinicalTrials.gov) | September 10, 201920190910 | 4/3/201920190304 | Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease Identification of Predictive Biomarkers for Response to Biologic Therapies andTofacitinib in Inflamm ... | Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches Identification of Predictive Biomarkers for Response to Biologic Therapies andTofacitinib in Inflamm ... | Inflammatory Bowel Diseases;Crohn Disease;Ulcerative Colitis | Biological: Infliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | NULL | Completed | 18 Years | N/A | All | 180 | Phase 4 | Spain |
97. 潰瘍性大腸炎
臨床試験数 : 3,305 / 薬物数 : 1,646 - (DrugBank : 318) / 標的遺伝子数 : 165 - 標的パスウェイ数 : 220
Showing 1 to 10 of 23 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT06269185 (ClinicalTrials.gov) | March 6, 202420240306 | 9/2/202420240209 | Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis | Comparison of Short and Long-term Efficacy Between Infliximab and Adalimumab on Patients With Ulcerative Colitis - a Retrospective Observational Multicenter Cohort Study Comparison of Short andLong-term Efficacy Between Infliximab and Adalimumabon Patients With Ulcerati ... | Ulcerative Colitis;Inflammatory Bowel Diseases | Drug: Infliximab;Drug: Adalimumab | Vastra Gotaland Region | NULL | Completed | 18 Years | 100 Years | All | 271 | Sweden | |
| 2 | NCT05313620 (ClinicalTrials.gov) | April 1, 202220220401 | 2/9/202120210902 | Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events | Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events | Ulcerative Colitis;Thromboembolism | Drug: Tofacitinib;Drug: Infliximab Adalimumab y Golimumab | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | NULL | Recruiting | 18 Years | N/A | All | 30 | Phase 4 | Spain |
| 3 | NCT05291039 (ClinicalTrials.gov) | January 1, 202220220101 | 12/3/202220220312 | Infliximab and Adalimumab in Inflammatory Bowel Disease Patients. | Assessment of Trough Levels and Efficacy of Infliximab and Adalimumab in Inflammatory Bowel Disease Patients. Assessment of Trough Levels andEfficacy of Infliximab and Adalimumabin Inflammatory Bowel Disease Pa ... | Inflammatory Bowel Diseases | Drug: Infliximab;Drug: Adalimumab | Rehab Werida | NULL | Completed | 18 Years | 80 Years | All | 56 | N/A | Egypt |
| 4 | EUCTR2020-001811-26-BE (EUCTR) | 18/11/202120211118 | 22/07/202120210722 | IBD under control with less medication | De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring - FREE-study De-escalation of anti-TNF therapy in adolescents andyoung adults with IBD with tight faecal calprote ... | Crohn's disease, ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Crohn's disease, ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] ... | Trade Name: Remicade INN or Proposed INN: INFLIXIMAB Trade Name: Flixabi INN or Proposed INN: INFLIXIMAB Trade Name: Inflectra INN or Proposed INN: INFLIXIMAB Trade Name: Remsima INN or Proposed INN: INFLIXIMAB Trade Name: Zessly INN or Proposed INN: INFLIXIMAB Trade Name: Humira INN or Proposed INN: ADALIMUMAB Trade Name: Amgevita INN or Proposed INN: ADALIMUMAB Trade Name: Hulio INN or Proposed INN: ADALIMUMAB Trade Name: Remicade INN or Proposed INN: INFLIXIMAB Trade Name: Flixabi INN or Proposed INN: INFLIXIMA ... | University Medical Center Groningen | NULL | Not Recruiting | Female: yes Male: yes | 148 | Phase 4 | Netherlands;Belgium;Spain | ||
| 5 | EUCTR2021-002211-65-ES (EUCTR) | 13/08/202120210813 | 11/06/202120210611 | EFFECT OF TOFACITINIB ON COAGULATION | EFFECT OF TOFACITINIB ON COAGULATION AND PLATELET FUNCTION, AND ITS ROLE IN THROMBOEMBOLIC EVENTS | ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 100000004856 MedDRA version: 20.0;Level: PT;Classification code 10009790;Term: Coagulation time;System Organ Class: 10022891 - Investigations MedDRA version: 21.0;Classification code 10061684;Term: Platelet function test;System Organ Class: 10022891 - Investigations;Therapeutic area: Body processes [G] - Biological Phenomena [G16] ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative col ... | Trade Name: Adalimumab INN or Proposed INN: ADALIMUMAB Trade Name: Infliximab INN or Proposed INN: INFLIXIMAB Trade Name: Golimumab INN or Proposed INN: GOLIMUMAB Trade Name: Tofacitinib INN or Proposed INN: TOFACITINIB Trade Name: Adalimumab INN or Proposed INN: ADALIMUMAB Trade Name: Infliximab INN or Proposed INN: INFL ... | Fundación Española de Gastroenterología | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 4 | Spain | ||
| 6 | EUCTR2019-002942-19-NO (EUCTR) | 16/03/202120210316 | 12/10/202020201012 | Nordic study of treatment strategy in inflammatory bowel disease | NORDTREATThe Nordic IBD treatment strategy trial – a randomized controlled trial of access to a protein profile NORDTREATThe Nordic IBD treatment strategy trial – a randomized controlled trial of access to a prot ... | Crohn's disease and Ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Crohn's disease andUlcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C0 ... | Trade Name: Remicade Trade Name: Humira Trade Name: Imurel Trade Name: Puri-nethol | Region Örebro län | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 4 | Norway;Denmark;Iceland | ||
| 7 | EUCTR2019-002942-19-DK (EUCTR) | 12/03/202120210312 | 05/11/202020201105 | Nordic study of treatment strategy in inflammatory bowel disease | NORDTREATThe Nordic IBD treatment strategy trial – a randomized controlled trial of access to a protein profile NORDTREATThe Nordic IBD treatment strategy trial – a randomized controlled trial of access to a prot ... | Crohn's disease and Ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;Term: Ulcerative colitis;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0;Classification code 10013099;Term: Disease Crohns;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Crohn's disease andUlcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10045365;T ... | Trade Name: Remicade INN or Proposed INN: INFLIXIMAB Trade Name: Humira INN or Proposed INN: ADALIMUMAB Trade Name: Imurel INN or Proposed INN: Azathioprine Trade Name: Puri-nethol INN or Proposed INN: MERCAPTOPURINE Trade Name: Remicade INN or Proposed INN: INFLIXIMAB Trade Name: Humira INN or Proposed INN: ADALIMUMAB ... | Region Örebro län | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 4 | Denmark;Iceland | ||
| 8 | NCT04646187 (ClinicalTrials.gov) | March 11, 202120210311 | 20/11/202020201120 | De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease | De-escalation of Anti-TNF Therapy in Adolescents and Young Adults With IBD With Tight Faecal Calprotectin and Trough Level Monitoring De-escalation of Anti-TNF Therapy in Adolescents andYoung Adults With IBD With Tight Faecal Calprote ... | Inflammatory Bowel Diseases;Crohn Disease;Colitis, Ulcerative | Biological: Infliximab;Biological: Adalimumab | University Medical Center Groningen | European Crohn´s and Colitis Organisation;Bühlmann Laboratories AG | Enrolling by invitation | 12 Years | 25 Years | All | 148 | Phase 4 | Belgium;Netherlands;Spain |
| 9 | EUCTR2019-002942-19-IS (EUCTR) | 25/01/202120210125 | 31/05/202420240531 | Nordic study of treatment strategy in inflammatory bowel disease | NORDTREATThe Nordic IBD treatment strategy trial – a randomized controlled trial of access to a protein profile NORDTREATThe Nordic IBD treatment strategy trial – a randomized controlled trial of access to a prot ... | Crohn's disease and Ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Crohn's disease andUlcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C0 ... | Trade Name: Remicade Trade Name: Humira Trade Name: Imurel Trade Name: Puri-nethol Trade Name: Metotrexat Trade Name: Folacin Trade Name: Remicade Trade Name: Humira Trade Name: Imurel Trade Name: Puri-nethol Trade Name: Metotrexa ... | Region Örebro län | NULL | Not Recruiting | Female: yes Male: yes | 250 | Phase 4 | Denmark;Iceland | ||
| 10 | EUCTR2020-001811-26-NL (EUCTR) | 30/09/202020200930 | 08/07/202020200708 | IBD under control with less medication | De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring - FREE-study De-escalation of anti-TNF therapy in adolescents andyoung adults with IBD with tight faecal calprote ... | Crohn's disease, ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] Crohn's disease, ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] ... | Trade Name: Remicade INN or Proposed INN: INFLIXIMAB Trade Name: Flixabi INN or Proposed INN: INFLIXIMAB Trade Name: Inflectra INN or Proposed INN: INFLIXIMAB Trade Name: Remsima INN or Proposed INN: INFLIXIMAB Trade Name: Zessly INN or Proposed INN: INFLIXIMAB Trade Name: Humira INN or Proposed INN: ADALIMUMAB Trade Name: Amgevita INN or Proposed INN: ADALIMUMAB Trade Name: Hulio INN or Proposed INN: ADALIMUMAB Trade Name: Remicade INN or Proposed INN: INFLIXIMAB Trade Name: Flixabi INN or Proposed INN: INFLIXIMA ... | University Medical Center Groningen | NULL | Not Recruiting | Female: yes Male: yes | 150 | Phase 4 | Netherlands;Belgium;Spain |